Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40% of patients
with psoriasis will go on to develop PsA, usually within 5–10 years of cutaneous disease …

Objectives To review the pathophysiology, co-morbidities, and therapeutic options for
psoriasis, psoriatic arthritis and rheumatoid arthritis in order to further understand the …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Abstract Objective To update the European League Against Rheumatism (EULAR)
recommendations for the pharmacological treatment of psoriatic arthritis (PsA). Methods …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

Background Early intervention and tight control of inflammation optimise outcomes in
rheumatoid arthritis but these approaches have not yet been studied in psoriatic arthritis. We …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and
systemic flushing accompanied by extensive sterile pustules. The committee of the …

Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international
recommendations for PMR treatment are not currently available. In this paper, we report the …